# Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

> **NCT05203419** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** MHS552
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05203419
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-15
- **Primary completion:** 2023-06-04
- **Final completion:** 2023-06-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203419, "Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05203419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*